Regulatory & Compliance

The United States finds itself at a critical juncture with a historic 41-day government shutdown, the longest in national history, colliding with a heated debate over extending enhanced Affordable Care Act (ACA) subsidies. This dual crisis has left millions of Americans grappling with halted

I'm thrilled to sit down with James Maitland, a renowned expert in healthcare policy and antitrust regulation with a deep understanding of how hospital mergers impact communities and markets. With years of experience analyzing the intersection of healthcare access, pricing, and competition, James

In the realm of orthopedic advancements, a staggering challenge looms over hip replacement surgeries: the risk of post-surgical infections that, though rare, can turn deadly with alarming consequences for patients, affecting just 1% to 2% of primary hip replacement cases. These infections carry a

In a nation where the cost of life-saving medications can bankrupt families, a staggering statistic emerges: biologic drugs, vital for treating conditions like cancer and rheumatoid arthritis, often cost patients upwards of $50,000 annually, creating a significant barrier to access. This leaves

Navigating the Medicare Payment Crisis in Diagnostic Labs In the complex landscape of U.S. healthcare, a staggering threat looms over diagnostic laboratories as Medicare reimbursement cuts for nearly 800 tests, with reductions as steep as 15%, are set to impact the market, prompting urgent calls

The 340B Drug Pricing Program, launched by the federal government in 1992, was designed with a noble purpose: to help safety-net hospitals and clinics provide affordable care to low-income and uninsured individuals by mandating steep drug discounts from manufacturers. However, over the decades,